ORPHA:35121
Lysosomal acid phosphatase deficiency
Publications
1,034
Trials
0
Interventional, condition-specific
Researchers
227
Distinct authors in sample
Gene link
ACP2
Limited
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare lysosomal disease characterized by intermittent vomiting, , lethargy, opisthotonos, and fatal outcome in early infancy, associated with deficient acid phosphatase in lysosomes. There have been no further descriptions in the literature since 1970.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008705
- MeSH:C562645
- OMIM:200950
- UMLS:C0268410
Additional Mondo synonyms (2)
acid phosphatase deficiency · lysosomal acid phosphatase deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Limited — ACP2
- LiteraturePresent
1,034 matched papers (594 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for ACP2.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,034
1,034 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,034 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
594 in the last 10 years · low confidence
Phrase hits: 47 · MeSH hits: 0
Who's working on it?
227
Distinct author names in 47 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01McKusick VA3 papers · 1993
Center for Medical Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21287-4922.
Papers in Europe PMC - 02Briggs TA2 papers · 2017
Manchester Academic Heath Science Centre, University of Manchester, Genetic Medicine, Manchester, UK.
Papers in Europe PMC - 03Crow YJ2 papers · 2017
University of Manchester, Manchester, UK, and Institut Imagine, Laboratory of Neurogenetics and Neuroinflammation, Paris, France.
Papers in Europe PMC - 04
- 05
- 06
- 07
- 08Alarcón-Riquelme ME1 paper · 2017
Universidad de Granada-Junta de Andalucía, Granada, Spain, and Oklahoma Medical Research Foundation, Oklahoma City.
Papers in Europe PMC - 09Amato AA1 paper · 2019
Department of Neurology, Harvard Medical School, Brigham Women's Hospital, Boston, Massachusetts, USA.
Papers in Europe PMC - 10Amberger JS1 paper · 1993Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 14 · after dedupe 14 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 14 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (14)
- isrctn·ISRCTN15384496·No longer recruiting·The ARTEMIS trial is for patients who have been diagnosed as having a cancer of the lower bowel, known as the rectum. This study will examine the benefit of adding an additional treatment alongside radiotherapy and chemotherapy with the hope of increasing the chance of curing rectal cancer without the need for surgery.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47106904·No longer recruiting·Gene therapy for a rare disorder caused by an enzyme deficiency
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12348610·No longer recruiting·Safety and effectiveness of WF10 for diabetes-related blood vessel diseases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54640699·No longer recruiting·A study to see if a new generic form of primaquine is the same as the one currently on the market
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22012044·No longer recruiting·Vitamin K in kidney transplant organ recipients: Investigating the effect on vessel stiffness
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN07034656·No longer recruiting·Biochemical Efficacy and Safety Trial of vitamin D (BEST-D)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83171665·No longer recruiting·FOCUS 3 - the feasibility of molecular selection of therapy using KRAS, BRAF and topo-1 in patients with metastatic or locally advanced colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68738654·No longer recruiting·Dose-intensified rechallenge with temozolomide, one week on one week off versus three weeks on one week off in patients with progressive or recurrent glioblastoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37909269·No longer recruiting·Understanding the mechanism of the acute phase response following intravenous (IV) bisphosphonates and its prevention: a study of the effects of zoledronic acid and co-prescription with fluvastatin or placebo
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50181543·No longer recruiting·Radiation therapy plus capecitabine and oxaliplatin chemotherapy and bevacizumab anti-angiogenetic therapy in locally advanced rectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30019040·No longer recruiting·HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38375681·No longer recruiting·A two-arm phase II randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of patients with K-ras-normal (wild-type) metastatic colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65243779·No longer recruiting·A phase IIa, open label study of visilizumab for the treatment of perianal fistulas in patients with Crohn's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16473514·No longer recruiting·A Phase IIa, Open-Labelled Study of Visilizumab in Patients with Moderate to Severe Inflammatory, Non-Stricturing, Non-Penetrating Forms of Crohn's Disease
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Lysosomal acid phosphatase deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Lysosomal acid phosphatase deficiency" OR "acid phosphatase deficiency") OR ("ACP2" OR "ACP2 syndrome" OR "ACP2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Lysosomal acid phosphatase deficiency" OR "acid phosphatase deficiency"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1034) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T23:44:57.945Z
